

Efavirenz + lamivudine + tenofovir

Statut de médicament essentiel

Description générale

A fixed-dose combination of two nucleoside reverse-transcriptase inhibitors (NRTIs, lamivudine and tenofovir disoproxil fumarate) and a non-nucleoside reverse transcriptase inhibitor (NNRTI, efavirenz) for treatment of human immunodeficiency virus (HIV) disease.

INN

Efavirenz + lamivudine + tenofovir

Codes ATC

[J05AR11](#)

Type de médicament

Chemical agent

Historique des statuts LME

Ajouté pour la première fois en 2017 ([TRS 1006](#)) pour [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Modifié en 2021 ([TRS 1035](#)) pour [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Équivalent thérapeutique pour

[efavirenz + emtricitabine + tenofovir](#) pour [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipédia

[Efavirenz + lamivudine + tenofovir](#)

DrugBank

[Efavirenz](#),

[Lamivudine](#),

[Tenofovir disoproxil](#)

Recommandations

Section

Fixed-dose combinations of antiretrovirals

- Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)